Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

rifampicin 150mg,isoniazide 75mg

Canada - English - Health Canada

laboratoires confab inc - isoniazid - tablet - 100mg - isoniazid 100mg - antituberculosis agents

Namibia - English - Namibia Medicines Regulatory Council

aventis pharma (pty) limited - rifampicin, isoniazide, pyrazinamide, ethambutol - tablets - rifampicin 120mg, isoniazide 60mg, pyrazinamide 300mg, ethambutol 200mg

Ireland - English - HPRA (Health Products Regulatory Authority)

sedana medical ab - isoflurane - inhalation vapour, liquid - 100 percent volume/volume - isoflurane

Bangladesh - English - DGDA (Directorate General of Drug Administration)

gonoshasthaya pharmaceuticals ltd. - isoniazid - tablet - 300 mg

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with e

United States - English - NLM (National Library of Medicine)

sti pharma llc - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hydrochloride 400 mg - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with ethambutol hcl have included cycloserine, ethionamide, pyrazinamide, viomycin and other drugs. isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. alternating drug regimens have also been utilized. ethambutol hcl is contraindicated in patients who are known to be hypersensitive to this drug. it is also contraindicated in patients with known optic neuritis unless clinical judgment determines that it may be used. ethambutol hcl is contraindicated in patients who are unable to appreciate and report visual side effects or changes in vision (e.g., young children, unconscious patients).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ethambutol hydrochloride (unii: qe4vw5fo07) (ethambutol - unii:8g167061qz) - ethambutol hcl is indicated for the treatment of pulmonary tuberculosis. it should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. selection of the companion drug should be based on clinical experience, considerations of comparative safety, and appropriate in vitro susceptibility studies. in patients who have not received previous antituberculous therapy, ie, initial treatment, the most frequently used regimens have been the following: ethambutol hcl plus isoniazidethambutol hcl plus isoniazid plus streptomycin. in patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. consequently, in such retreatment patients, ethambutol hcl should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. antituberculous drugs used with e